Brokerages Set Aura Biosciences, Inc. (NASDAQ:AURA) PT at $23.00

Aura Biosciences, Inc. (NASDAQ:AURA) has received a consensus recommendation of “Buy” from the seven brokerages that are currently covering the company, Marketbeat reports. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $23.00.

Several equities analysts recently commented on AURA shares. HC Wainwright reissued a “buy” rating and issued a $22.00 target price on shares of Aura Biosciences in a report on Thursday, November 14th. Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st.

Insider Activity at Aura Biosciences

In related news, insider Los Pinos Elisabet De sold 15,955 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total transaction of $122,374.85. Following the transaction, the insider now owns 304,692 shares in the company, valued at $2,336,987.64. This trade represents a 4.98 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold 23,045 shares of company stock valued at $177,242 in the last ninety days. Insiders own 5.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of AURA. Long Focus Capital Management LLC increased its stake in Aura Biosciences by 123.9% in the fourth quarter. Long Focus Capital Management LLC now owns 2,537,774 shares of the company’s stock valued at $20,861,000 after purchasing an additional 1,404,228 shares during the period. Levin Capital Strategies L.P. grew its stake in shares of Aura Biosciences by 169.1% in the 4th quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company’s stock valued at $10,255,000 after purchasing an additional 783,984 shares during the last quarter. B Group Inc. acquired a new position in shares of Aura Biosciences in the fourth quarter valued at approximately $3,885,000. Franklin Resources Inc. raised its stake in shares of Aura Biosciences by 14.8% during the third quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company’s stock worth $15,571,000 after purchasing an additional 215,597 shares during the last quarter. Finally, Ensign Peak Advisors Inc raised its stake in shares of Aura Biosciences by 43.3% during the fourth quarter. Ensign Peak Advisors Inc now owns 390,695 shares of the company’s stock worth $3,212,000 after purchasing an additional 118,000 shares during the last quarter. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Aura Biosciences Trading Down 1.6 %

Shares of NASDAQ:AURA opened at $7.51 on Thursday. Aura Biosciences has a 52 week low of $6.63 and a 52 week high of $12.38. The company’s 50 day moving average is $7.99 and its two-hundred day moving average is $8.73. The company has a market cap of $375.12 million, a PE ratio of -4.34 and a beta of 0.29.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.